Enovis Corp
ENOV
17.69
+0.26
+1.49%
Enovis Corp
US · ENOV
#3237 by market cap
17.69
+0.26
+1.49%
Live - 5344 symbols - heartbeat 149s ago
· 2026-10-09 19:30
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 0.49, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +6.66% YoY
Margins
- Gross margin
- 59.84%
- Operating margin
- -0.84%
- Net margin
- -52.69%
Key ratios & quality
- Enterprise valuei
- 2.31B
- Altman Z-Scorei
- 0.49
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.19B | 3.33B | 1.12B | 1.43B | 1.56B | 1.71B | 2.11B | 2.25B |
| Gross profit | 729.38M | 1.40B | 603.64M | 777.68M | 869.38M | 990.78M | 1.18B | 1.35B |
| Selling & admin expenses | 548.76M | 1.13B | 515.47M | 665.78M | 772.91M | 830.31M | 1.03B | 1.07B |
| Research & development | -- | -- | 34.27M | 49.09M | 60.83M | 75.33M | 91.30M | 120.33M |
| Operating profit | 180.61M | 268.91M | -49.40M | -54.11M | -90.66M | -48.37M | -103.43M | -18.87M |
| Pretax profit | 92.36M | 50.49M | -119.01M | -121.78M | -2.07M | -67.13M | -822.92M | -1.16B |
| Tax | -29.51M | 31.63M | -44.58M | -19.53M | 36.12M | -13.29M | 4.49M | 22.29M |
| Net profit | 154.47M | -517.15M | 45.77M | 76.28M | -11.76M | -32.73M | -824.82M | -1.18B |
| Basic EPS | 4 | -12 | 1 | 1 | 0 | -1 | -15 | -21 |
| Diluted EPS | 3.48 | -11.67 | 0.93 | 1.40 | -0.25 | -0.61 | -14.93 | -20.75 |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2025-12 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Revenue | 558.83M | 564.55M | 548.91M | 575.76M | 589.15M | 582.78M |
| Gross profit | 332.23M | 334.70M | 328.91M | 349.42M | 365.49M | 359.25M |
| Selling & admin expenses | 269.02M | 267.07M | 263.62M | 270.44M | 282.81M | 263.73M |
| Research & development | 28.53M | 30.70M | 29.74M | 31.37M | 31.53M | 31.69M |
| Operating profit | -42.91M | -16.08M | -8.14M | 48.25M | 9.24M | 22.27M |
| Pretax profit | -57.35M | -25.65M | -566.87M | -509.55M | 634.00K | 7.47M |
| Tax | -1.77M | 10.80M | 4.01M | 9.26M | 9.05M | 8.50M |
| Net profit | -55.71M | -36.55M | -570.91M | -520.45M | -8.45M | -1.04M |
| Basic EPS | -1 | -1 | -10 | -9 | 0 | 0 |
| Diluted EPS | -0.99 | -0.64 | -9.99 | -9.10 | -0.15 | -0.02 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.96B | 1.40B | 1.36B | 2.30B | 795.02M | 896.52M | 1.15B | 1.21B |
| Cash & ST investments | 77.15M | 109.63M | 97.07M | 680.25M | 24.30M | 36.19M | 48.17M | 36.39M |
| Inventory | 359.66M | 571.56M | 564.82M | 356.23M | 426.64M | 468.83M | 547.12M | 584.38M |
| Total assets | 6.62B | 7.39B | 7.35B | 8.52B | 4.27B | 4.51B | 4.72B | 3.83B |
| Total current liabilities | 1.20B | 857.31M | 811.66M | 1.02B | 565.20M | 369.61M | 529.00M | 598.47M |
| Short-term debt | 5.02M | 67.66M | 66.77M | 29.64M | 243.56M | 21.57M | 42.37M | 59.74M |
| Long-term debt | 1.19B | 2.28B | 2.20B | 2.08B | 40.00M | 466.16M | 1.31B | 1.26B |
| Total liabilities | 3,139,012,000.00 | 3,897,204,000.00 | 3,763,675,000.00 | 3,854,479,000.00 | 823,447,000.00 | 1,088,633,000.00 | 2,154,448,000.00 | 2,342,835,000.00 |
| Total equity | 3.48B | 3.49B | 3.59B | 4.66B | 3.45B | 3.42B | 2.56B | 1.49B |
| Retained earnings | 991.84M | 479.56M | 517.37M | 589.02M | 575.73M | 542.47M | -283.02M | -1.47B |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2025-12 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Total current assets | -- | 1.28B | 1.28B | 1.21B | 1.24B | 1.21B |
| Cash & ST investments | -- | 44.07M | 33.62M | 36.39M | 33.13M | 12.56M |
| Inventory | -- | 628.22M | 613.75M | 584.38M | 602.54M | 601.66M |
| Total assets | -- | 5.02B | 4.43B | 3.83B | 3.83B | 3.77B |
| Total current liabilities | -- | 568.18M | 575.44M | 598.47M | 608.67M | 612.05M |
| Short-term debt | -- | 43.08M | 44.03M | 59.74M | 60.23M | 62.77M |
| Long-term debt | -- | 1.37B | 1.34B | 1.26B | 1.29B | 1.25B |
| Total liabilities | -- | 2,440,438,000.00 | 2,409,689,000.00 | 2,342,835,000.00 | 2,352,764,000.00 | 2,286,961,000.00 |
| Total equity | -- | 2.58B | 2.02B | 1.49B | 1.48B | 1.48B |
| Retained earnings | -- | -375.73M | -946.87M | -1.47B | -1.48B | -1.48B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 226.37M | 130.95M | 301.94M | 356.10M | -55.86M | 134.99M | 113.50M | 217.29M |
| Depreciation & amortization | 141.88M | 236.03M | 246.23M | 262.92M | 219.71M | 217.11M | 284.80M | 294.38M |
| Free cash flow | 156.72M | 5.55M | 187.15M | 251.86M | -161.31M | 12.77M | -67.21M | 19.92M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -195.30M | 11.88M | 3.50M | 745.18M | 5.81M | 1.78M | 1.87M | 1.32M |
| Ending cash balance | 245.02M | 109.63M | 101.07M | 719.37M | 24.30M | 44.83M | 48.17M | 36.39M |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2025-12 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Operating cash flow | -- | 47.77M | 82.58M | 88.54M | 23.95M | 75.03M |
| Depreciation & amortization | -- | 71.55M | 74.38M | 77.01M | 73.36M | 71.03M |
| Free cash flow | -- | 3.40M | 29.09M | 32.29M | -28.85M | 31.14M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 788.00K | 189.00K | 0 | 628.00K | 380.00K |
| Ending cash balance | -- | 44.07M | 33.62M | 36.39M | 33.13M | 12.56M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 4.14 | -15.72 | 1.22 | 1.76 | -0.33 | -0.97 | -27.61 | -58.46 |
| ROA %i | 2.11 | -7.54 | 0.58 | 0.90 | -0.21 | -0.76 | -17.89 | -27.69 |
| ROIC %i | 4.08 | -8.47 | 2.00 | 1.79 | 0.11 | -0.45 | -19.70 | -33.85 |
| 5-year avg ROE %i | 6.33 | 0.57 | -0.27 | -0.78 | -1.79 | -2.81 | -5.19 | -17.12 |
| EBIT margin %i | 6.19 | 5.11 | 5.29 | 6.17 | 1.41 | -2.78 | -36.34 | -50.03 |
| FCF / sales %i | 4.27 | 0.17 | 6.09 | 6.53 | -- | 0.75 | -- | 0.89 |
| Current ratioi | 1.63 | 1.64 | 1.68 | 2.25 | 1.41 | 2.43 | 2.17 | 2.02 |
| Quick ratioi | 0.39 | 0.78 | 0.76 | 0.91 | 0.52 | 0.89 | 0.86 | 0.80 |
| Debt / assetsi | 18.10 | 33.68 | 32.78 | 25.42 | 7.84 | 11.90 | 29.76 | 35.97 |
| LT debt / equityi | 36.47 | 70.34 | 66.13 | 46.24 | 2.65 | 15.06 | 53.15 | 88.60 |
| Interest coveragei | 5.15 | 1.42 | 1.56 | 3.28 | 0.91 | -2.40 | -13.41 | -32.29 |
| Revenue CAGR (3Y) %i | -13.89 | 1.46 | -16.68 | -13.36 | -22.26 | 15.06 | 13.90 | 12.88 |
| Net income CAGR (3Y) %i | -5.80 | -- | -34.41 | -20.05 | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -12.50 | -68.86 | 7.65 | 17.13 | -- | -59.14 | -- | -- |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2025-12 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -28.22 | -51.10 | -58.46 | -55.55 | -54.33 |
| ROA %i | -- | -15.82 | -27.39 | -27.69 | -26.12 | -25.07 |
| ROIC %i | -- | -18.23 | -32.62 | -33.85 | -32.06 | -31.40 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -34.74 | -57.64 | -50.03 | -46.82 | -45.06 |
| FCF / sales %i | -- | -- | 1.02 | 0.89 | 1.58 | 2.77 |
| Current ratioi | -- | 2.25 | 2.22 | 2.02 | 2.04 | 1.98 |
| Quick ratioi | -- | 0.88 | 0.81 | 0.80 | 0.78 | 0.74 |
| Debt / assetsi | -- | 29.17 | 32.51 | 35.97 | 36.81 | 36.35 |
| LT debt / equityi | -- | 55.14 | 69.15 | 88.60 | 91.43 | 88.44 |
| Interest coveragei | -- | -19.70 | -35.38 | -32.29 | -30.65 | -30.84 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Reconstructive is the largest reported line at 50.54% of revenue, across 2 reported segments.
- Prevention & Recovery follows at 49.46%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Reconstructive50.54%
Prevention & Recovery49.46%
Quote time 2026-10-09 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Enovis Corp discussion 0 comments